Response-guided treatment of cirrhotic chronic hepatitis B patients: Multicenter prospective study

World Journal of Gastroenterology

Volumn 21, Issue 2, 2015, Pages 644-651

  Gu, Er Li ^a   Yu, Yi Qi ^a   Wang, Jia Li ^b   Ji, Yan Yan ^c   Ma, Xiu Yun ^d   Xie, Qing ^e   Pan, Hong Ying ^f   Wu, Shan Min ^g   Li, Jun ^h   Chen, Cheng Wei ^a   Xu, Xiao Wei ^a   Wang, Yue Er ^a   Yao, Guang Bi ^b   Wang, Hong ^a   Zhang, Wen Hong ^a  

^a FUDAN UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

^d The 6th People's Hospital   (China)

^e Shanghai Public Health Center   (China)

^f Department of Cadre Health Care   (China)

^g Shanghai Liver Disease Research Center of Nanjing Military Region of PLA   (China)

^h ZHEJIANG UNIVERSITY   (China)

Author keywords

Adefovir dipivoxil; Cirrhosis; Hepatitis B; Lamivudine; Response guided therapy

Indexed keywords

ADEFOVIR; ALBUMIN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA; ADENINE; ANTIVIRUS AGENT; BIOLOGICAL MARKER; PHOSPHONIC ACID DERIVATIVE;

ADD ON THERAPY; ADULT; ALBUMIN BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS; COHORT ANALYSIS; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIDRUG RESISTANCE; MUTATION RATE; PROSPECTIVE STUDY; SEROCONVERSION; CHINA; CHRONIC HEPATITIS B; DISEASE COURSE; LIVER CIRRHOSIS; REVIEW; VIRUS INHIBITION; VIRUS MUTATION; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; GENETICS; GENOTYPE; HEPATITIS B, CHRONIC; MIDDLE AGED; MUTATION; TIME; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADENINE; ADULT; ANTIVIRAL AGENTS; BIOMARKERS; CHINA; DNA, VIRAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MUTATION; ORGANOPHOSPHONATES; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84964696116     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i2.644     Document Type: Article

References (20)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107 [PMID: 14996343]
2. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology 2009; 49: S45-S55 [PMID: 19399792 DOI: 10.1002/hep.22898]
3. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73 [PMID: 16391218]
4. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-686 [PMID: 16530509]
5. Ahn SH, Chan HL, Chen PJ, Cheng J, Goenka MK, Hou J, Lim SG, Omata M, Piratvisuth T, Xie Q, Yim HJ, Yuen MF. Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. Hepatol Int 2010; 4: 386-395 [PMID: 20305758 DOI: 10.1007/s12072-010-9163-9]
6. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, Brown N, Woessner M, Boehme R, Condreay L. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-696 [PMID: 12627352]
7. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373: 582-592 [PMID: 19217993 DOI: 10.1016/S0140-6736(09)60207-5]
8. Yatsuji H, Suzuki F, Sezaki H, Akuta N, Suzuki Y, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Watahiki S, Iwasaki S, Kobayashi M, Kumada H. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. J Hepatol 2008; 48: 923-931 [PMID: 18433925 DOI: 10.1016/j.jhep.2008.02.019]
9. Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, Moorat A, Gardner S, Woessner M, Bourne E, Brosgart CL, Schiff E. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 81-90 [PMID: 14699490]
10. Keeffe EB, Zeuzem S, Koff RS, Dieterich DT, Esteban-Mur R, Gane EJ, Jacobson IM, Lim SG, Naoumov N, Marcellin P, Piratvisuth T, Zoulim F. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007; 5: 890-897 [PMID: 17632041]
11. Kim MN, Lee CK, Ahn SH, Lee S, Kim SU, Kim do Y, Kim HS, Han KH, Chon CY, Park JY. Maintaining remission in lamivudine-resistant patients with a virological response to adefovir add-on lamivudine after stopping lamivudine therapy. Liver Int 2014; 34: 1543-1549 [PMID: 24330475 DOI: 10.1111/liv.12437]
12. Ridruejo E, Adrover R, Silva MO. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology 2011; 54: 1104-115; author reply 1105 [PMID: 21721024 DOI: 10.1002/hep.24498]
13. Lee YS, Suh DJ, Lim YS, Jung SW, Kim KM, Lee HC, Chung YH, Lee YS, Yoo W, Kim SO. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006; 43: 1385-1391 [PMID: 16729316]
14. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Addingon versus switching-to adefovir therapy in lamivudineresistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45: 307-313 [PMID: 17256746]
15. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, Tobias H. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6: 1315-141; quiz 1286 [PMID: 18845489 DOI: 10.1016/ j.cgh.2008.08.021]
16. Shin JW, Jung SW, Park BR, Kim CJ, Eum JB, Kim BG, Du Jeong I, Bang SJ, Park NH. HBV DNA level at 24 weeks is the best predictor of virological response to adefovir add-on therapy in patients with lamivudine resistance. Antivir Ther 2012; 17: 387-394 [PMID: 22293395 DOI: 10.3851/IMP1945]
17. Yuen MF, Fong DY, Wong DK, Yuen JC, Fung J, Lai CL. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology 2007; 46: 1695-1703 [PMID: 18027877]
18. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001; 34: 785-791 [PMID: 11584376]
19. Yao GB, Zhu M, Cui ZY, Wang BE, Yao JL, Zeng MD. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China. J Dig Dis 2009; 10: 131-137 [PMID: 19426396 DOI: 10.1111/ j.1751-2980.2009.00375.x]
20. Liaw YF. On-treatment outcome prediction and adjustment during chronic hepatitis B therapy: now and future. Antivir Ther 2009; 14: 13-22 [PMID: 19320233]